CSF2 and non-small cell lung carcinoma: Hence, the triple combination of SBRT, GM-CSF and a PD-1/PD-L1 inhibitor may potentially enhance the treatment efficacy of advanced NSCLC through the activation of innate and adaptive anti-tumour immune responses.